



Infection, Virulence and Drug Resistance of Fungal Pathogen

Guest Editor:

Message from the Guest Editor

Prof. Dr. Changbin Chen

The Center for Microbes,
Development and Health, Key
Laboratory of Molecular Virology
and Immunology, Institut Pasteur
of Shanghai, Chinese Academy of
Sciences, Shanghai 200031,
China

Dear Colleagues,

Billions of people suffer from the growing incidence of fungal infection every year, with high morbidity and mortality rate. However, the current arsenal of antifungals is exceedingly limited due to a lack of new drug targets and the emergence of drug resistance. Furthermore, the rapid spread of the recently emerged “superbug” *Candida auris* further worsens the efficacy of first-line antifungal therapy. The diagnosis and treatment of human fungal infections remain a challenge, and tackling this challenge requires better understanding of the mechanisms contributing to fungal infection, pathogenicity, and antifungal drug resistance. A number of cutting-edge technologies, provide robust and effective tools to unravel mechanisms and identify novel targets. This Special Issue seeks manuscript submissions that further our understanding of fungal infection, virulence, and drug resistance. Submissions on the characterization of new antifungals, technologies, and antifungal strategies and mechanisms that are harnessed to combat fungal infection are especially encouraged.

Deadline for manuscript
submissions:
closed (15 March 2022)





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi